High prevalence of activated protein C resistance and factor v Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait

Diagnostic Molecular Pathology

Volumn 19, Issue 3, 2010, Pages 180-183

  Jadaon, Mehrez M ^a   Dashti, Ali A ^a   Lewis, Hend L ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

activated protein C resistance; Arabs; factor V Leiden mutation; Kuwait; PCR; RFLP

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; AGAR GEL ELECTROPHORESIS; ARAB; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KUWAIT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ARABS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HUMANS; KUWAIT; MALE; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; VENOUS THROMBOSIS;

EID: 77951739149     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-201009000-00009     Document Type: Article

References (40)

1. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost. 1995;74:1-6.
2. Kane WH, Davie EW. Blood coagulation factor V and VIII: structural and functional similarities and their relationship to haemorrhegic and thrombotic disorders. Blood. 1998;71:539-555.
3. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
4. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
5. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90: 1004-1008.
6. Dahlback B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays. Pros and Cons. Thromb Haemost. 1995;73:739-742.
7. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of Factor V Leiden in 4047 men and women. Implications for venous thrmoboembolism screening. JAMA. 1997;277:1305-1307.
8. Dahlback B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost. 1997;78:483-488.
9. Faioni EM, Razzari C, Martinelli I, et al. Resistance to activated protein C in unselected patients with arterial and venous thrombo sis. Am J Hematol. 1997;55:59-64.
10. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
11. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997; 89:397-402.
12. Hoagland LE, Triplett DA, Peng F, et al. APC-resistnace as measured by a Textarin time assay: comparison to the APTT-based method. Thromb Res. 1996;83:363-373.
13. Zoller B, Svensson PJ, He X, et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94: 2521-2524.
14. Alderborn A, Siegbahn A, Wadelius C. Venous thrombosis: factor V G1691A genotyping related to APC resistance measured by 2 methods. Eur J Haematol. 1997;58:229-232.
15. Bontempo FA, Hassett AC, Faruki H, et al. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg. 1997;25:271-275.
16. Florell SR, Rodgers GM. Inherited thrombotic disorders: an update. Am J Hematol. 1997;54:53-60.
17. Samama MM, Simon D, Horellou MH, et al. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemo-stasis. 1996;26:315-330.
18. Dahlback B, Hillarp A, Rosen S, et al. Resistance to activated protein C, the FV: Q506 allele, and the venous thrombosis. Ann Hematol. 1996;72:166-176.
19. Koeleman BPC, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol. 1997;34:256-264.
20. Cox MJ, Rees DC, Martinson JJ, et al. Evidence of a single origin of factor V Leiden. Br J Haematol. 1996;92:1022-1025.
21. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-G mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997; 336:399-403.
22. Leroyer C, Mercier B, Escoffre M, et al. Factor V Leiden prevalence in venous thromboembolism patients. Chest. 1997;111:1603-1606.
23. Bennett JA, Palmer LJ, Musk AW, et al. Prevalence of factor V Leiden and prothrombin 20210A mutations in indigenous Australians. Thromb Haemost. 2001;86:1592-1593.
24. Arruda VR, Annichino-Bizzacchi JM, Costa FF, et al. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol. 1995;49:242-243.
25. Zama T, Murata M, Ono F, et al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol. 1996;65:71-78.
26. Pepe G, Rickards O, Vanegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost. 1997;77:329-331.
27. Ho CH, Chau WK, Hsu HC, et al. Prevalence of factor V Leiden in the Chinese population. Zhonghua Yi Xue Za Zhi. 62:875-878.
28. De Maat MPM, Kluft C, Jespersen J, et al. World distribution of factor V Leiden mutation. Lancet. 1996;347:58.
29. Rosen E, Renbaum P, Heyd J, et al. High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost. 1999; 82:1768.
30. Almawi WY, Tamim H, Kreidy R, et al. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis. 2005;19:189-196.
31. Dzimiri N, Meyer B. World distribution of factor V Leiden. Lancet. 1996;347:481-482.
32. Irani-Hakime N, Tamim H, Elias G, et al. High prevalence of factor V mutation (Leiden) in the Eastern Mediterranean. Clin Chem. 2000;46:134-136.
33. Taher A, Khalil I, Shamseddine A, et al. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost. 2001;86:723-724.
34. Eid SS, Shubeilat T. Prevalence of Factor V Leiden, prothrombin G20210A, and MTHFR G677A among 594 thrombotic Jordanian patients. Blood Coagul Fibrinolysis. 2005;16:417-421.
35. El-Karaksy H, El-Koofy N, El-Hawary M, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol. 2004;83:712-715.
36. Pathare A, Al Kindi S, Al Haddabi H, et al. Hereditary thrombophilia in ethnic Omani patients. Am J Hematol. 2006;81:101-106.
37. Settin A, Dowaidar M, El-Baz R, et al. Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction. Hematology. 2008;13:170-174.
38. Pawar AR, Shetty S, Ghosh K, et al. How old is Factor V Leiden mutation? Thromb Haemost. 2001;86:1591-1592.
39. Zeinali S, Duca F, Zarbakhsh B, et al. Thrombophilic mutations in Iran. Thromb Haemost. 2000;83:351-352.
40. Mozafari H, Rahimi Z, Heidarpour A, et al. The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydro-folate reductase polymorphism C677T among G6PD deficient individuals from Western Iran. Mol Biol Rep. 2009;36:2361-2364.